Abstract | PURPOSE OF REVIEW:
Infection by Staphylococcus aureus in critically ill patients is usually associated with antimicrobial resistance and high mortality. A more effective antibiotic treatment is needed to replace older drugs that have limited efficacy. Novel substances active on methicillin-resistant Staphylococcus aureus, which are already available on the market or are still in development, are discussed in this review, with emphasis on nosocomial infections. RECENT FINDINGS: SUMMARY: For the moment, there are limited and rather expensive therapeutic options for the infections by Staphylococcus aureus in the critically ill. No dramatic superiority of the new drugs in comparison to the standard therapies was observed in most of the clinical trials. Better results on the efficacy of the drugs under investigation are expected.
|
Authors | Malina Schmidt-Ioanas, Andres de Roux, Hartmut Lode |
Journal | Current opinion in critical care
(Curr Opin Crit Care)
Vol. 11
Issue 5
Pg. 481-6
(Oct 2005)
ISSN: 1070-5295 [Print] United States |
PMID | 16175036
(Publication Type: Journal Article, Review)
|
Chemical References |
- Acetamides
- Aminoglycosides
- Anti-Bacterial Agents
- Cephalosporins
- Glycopeptides
- Lipoglycopeptides
- Oxazolidinones
- Virginiamycin
- quinupristin-dalfopristin
- ceftobiprole
- Teicoplanin
- Tigecycline
- dalbavancin
- Minocycline
- Linezolid
- Daptomycin
- oritavancin
- telavancin
|
Topics |
- Acetamides
(therapeutic use)
- Aminoglycosides
(therapeutic use)
- Anti-Bacterial Agents
(therapeutic use)
- Cephalosporins
(therapeutic use)
- Clinical Trials as Topic
- Critical Illness
- Daptomycin
(therapeutic use)
- Drug Resistance, Multiple, Bacterial
- Glycopeptides
(therapeutic use)
- Humans
- Linezolid
- Lipoglycopeptides
- Methicillin Resistance
- Minocycline
(analogs & derivatives, therapeutic use)
- Oxazolidinones
(therapeutic use)
- Staphylococcal Infections
(drug therapy)
- Teicoplanin
(analogs & derivatives, therapeutic use)
- Tigecycline
- Virginiamycin
(therapeutic use)
|